J&J Will Pay $181 Million to Settle Risperdal Ad Claims

Johnson & Johnson will pay $181 million to resolve claims by 36 states that it improperly marketed and advertised the antipsychotic drugs Risperdal and Invega.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.